Glucosamine Sulphate, Ginger, Ginger-Avocado-Soya and Ginger-Ibuprofen for Chronic Back Pain - Full Text View

Sponsor:	Ferrosan AS
Information provided by:	Ferrosan AS
ClinicalTrials.gov Identifier:	NCT00317655

Purpose

The main purpose of this study is to investigate the ability of some dietary supplement products to affect general joint health and life quality in a selected population with back pain.

The study is randomized and double - blind, with parallel groups receiving treatment for a duration of 12 weeks.

Condition	Intervention	Phase
Back Pain	Drug: Glucosamine sulphate Drug: Ginger Drug: Ginger-Avocado-Soya Drug: Ginger-ibuprofen	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Glucosamine Sulphate, Ginger, Ginger-Avocado-Soya and Ginger-Ibuprofen for Chronic Back Pain - a Randomized, Double Blind, Placebo-Controlled Clinical Investigation With Parallel Groups for 3 Months to Enlighten Joint Health

Resource links provided by NLM:

MedlinePlus related topics: Back Pain

Drug Information available for: Glucosamine hydrochloride Ibuprofen Glucosamine sulfate Glucosamine

U.S. FDA Resources

Further study details as provided by Ferrosan AS:

Primary Outcome Measures:

mm pain relief (visual analog scale [VAS]) during past 24 hours compared from start (0 weeks) and 12 weeks

Secondary Outcome Measures:

Percentage of responders showing more than 15 mm improvement in pain relief
mm pain relief (VAS) within past 7 days at weeks 1, 2, 4, 6, 9, and 12
Function level according to Roland Morris-questionnaire (23 points)
Patients' Global Impression of Change (pain)
Patients' satisfaction with pain medication
Use of rescue medication
Adverse events profile
Body weight (start and 12 weeks)

Enrollment:	175
Study Start Date:	April 2006
Study Completion Date:	April 2007

Eligibility

Ages Eligible for Study:	30 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Chronic back pain daily or almost daily for at least 3 months prior to inclusion
Patient classified as I or II according to Quebec Task Force
No intake of glucosamine sulphate, ginger, or avocado-soya extract during last 3 months
Fertile women should, at start, have a negative pregnancy test and during test use acceptable prevention methods (p-pills, intrauterine device [IUD], depot gestagen, subdermal implant, hormonal vaginal ring or transdermal depot plaster).
Anxiolytics, muscle relaxants, physiotherapy, chiropractic treatment, or training should not have been used during last 3 months.

Exclusion Criteria:

Serious disease (eg. heart disease, cancer (within past 5 years), kidney disease, blood diseases, inflammatory diseases (eg. chronic rheumatoid arthritis, fibromyalgia)
Suspicion that back pain is caused by osteoporosis, other arthritic condition than osteoarthritis, cancer, infection, pain from organ disease or psychosomatic cancer disease.
Uncontrolled elevated blood pressure, defined as systolic ≥ 160 mm Hg or diastolic ≥ 90 mm Hg.
VAS measurement at inclusion less than ved 30 mm or over 90 mm.
Prehistory of ulcer, stomach surgery, or inflammatory bowel disease
Pain relief medication besides must not be taken during study.
Patients in need of non-steroidal anti-inflammatory drugs (NSAIDs), morphine, or similar medication are not eligible. Same is also valid for patients in need of injections or acupuncture.
Back surgery within 6 months before inclusion or earlier surgery without effect
"Heart" aspirin (low dose), ulcer medication, or blood thinning medication
Alcohol abuse
Depression
Pregnancy or breastfeeding
Allergy to crustaceans or known intolerance for glucosamine sulphate, ginger, avocado, soy, or ibuprofen
Allergy or asthma released by salicylic acid or other arthritis medication (NSAIDs)
Patient who is seeking pension due to back pain or has other economical interests connected to his/her back pain

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00317655

Locations

Denmark
Slidgigtinstituttet A/S
Ishoj, Denmark, 2635

Sponsors and Collaborators

Ferrosan AS

Investigators

Principal Investigator:

Keld Østergaard, MD, PhD

Slidgigtinstituttet A/S

More Information

No publications provided

Study ID Numbers:	Jointcare/Fe/1/DK, Eudractnr. 2005-002691-15
Study First Received:	April 23, 2006
Last Updated:	May 16, 2007
ClinicalTrials.gov Identifier:	NCT00317655 History of Changes
Health Authority:	Denmark: Danish Medicines Agency

Keywords provided by Ferrosan AS:

back pain

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Ibuprofen
Molecular Mechanisms of Pharmacological Action
Cyclooxygenase Inhibitors
Nervous System Diseases
Physiological Effects of Drugs
Enzyme Inhibitors
Pain
Back Pain
Pharmacologic Actions

Signs and Symptoms
Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Neurologic Manifestations
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Peripheral Nervous System Agents
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 08, 2010